Severe Diabetes and Leptin Resistance Cause Differential Hepatic and Renal Transporter Expression in Mice by More, Vijay et al.
University of Rhode Island
DigitalCommons@URI
Biomedical and Pharmaceutical Sciences Faculty
Publications Biomedical and Pharmaceutical Sciences
2012
Severe Diabetes and Leptin Resistance Cause
Differential Hepatic and Renal Transporter
Expression in Mice
Vijay More
University of Rhode Island
Xia Wen
See next page for additional authors
Creative Commons License
Creative Commons License
This work is licensed under a Creative Commons Attribution 2.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted
for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
More, V. R., Wen, X., Thomas, P. E., Aleksunes, L. M., & Slitt, A. L. (2012). Severe diabetes and leptin resistance cause differential
hepatic and renal transporter expression in mice. Comparative Hepatology, 11:1. doi: 10.1186/1476-5926-11-1
Available at: http://dx.doi.org/10.1186/1476-5926-11-1
Authors
Vijay More, Xia Wen, Paul E. Thomas, Lauren M. Aleksunes, and Angela L. Slitt
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/4
RESEARCH Open Access
Severe diabetes and leptin resistance cause
differential hepatic and renal transporter
expression in mice
Vijay R More1, Xia Wen2, Paul E Thomas3, Lauren M Aleksunes2 and Angela L Slitt1*
Abstract
Background: Type-2 Diabetes is a major health concern in the United States and other Westernized countries, with
prevalence increasing yearly. There is a need to better model and predict adverse drug reactions, drug-induced liver
injury, and drug efficacy in this population. Because transporters significantly contribute to drug clearance and
disposition, it is highly significant to determine whether a severe diabetes phenotype alters drug transporter
expression, and whether diabetic mouse models have altered disposition of acetaminophen (APAP) metabolites.
Results: Transporter mRNA and protein expression were quantified in livers and kidneys of adult C57BKS and db/db
mice, which have a severe diabetes phenotype due to a lack of a functional leptin receptor. The urinary excretion of
acetaminophen-glucuronide, a substrate for multidrug resistance-associated proteins transporters was also
determined. The mRNA expression of major uptake transporters, such as organic anion transporting polypeptide
Slco1a1 in liver and kidney, 1a4 in liver, and Slc22a7 in kidney was decreased in db/db mice. In contrast, Abcc3 and
4 mRNA and protein expression was more than 2 fold higher in db/db male mouse livers as compared to C57BKS
controls. Urine levels of APAP-glucuronide, -sulfate, and N-acetyl cysteine metabolites were higher in db/db mice.
Conclusion: A severe diabetes phenotype/presentation significantly altered drug transporter expression in liver and
kidney, which corresponded with urinary APAP metabolite levels.
Keywords: Leptin, Diabetes, Transporters, Disposition, Acetaminophen
Background
The prevalence of obesity and metabolic syndrome has
increased at an alarming rate. By the year 2030, the number
of adults with either type-1 or type-2 diabetes is estimated
to be greater than 350 million [1]. Adult onset type-2 dia-
betes (T2DM) constitutes over 90% of all diabetes cases
and is characterized by insulin resistance, abnormal insulin
secretion, or both. Of these cases, it is estimated that 16%
of people have undiagnosed or poorly managed diabetes
(NIDDK National Health Interview survey, 2007–2009).
It is well documented that Type-2 diabetes and hepatic
steatosis are co-present [2]. The incidence of non-alcoholic
fatty liver disease (NAFLD) is prevalent in 40 to 70% of
patients with T2DM [3,4]. This type of liver disease origi-
nates as hepatic steatosis, and can progress to non-
alcoholic steatohepatitis (NASH), cirrhosis, and end stage
liver failure [5]. T2DM-related NAFLD is not fully under-
stood, but it is known that leptin and insulin are important
mediators in the progression of NAFLD [6]. Leptin is a
hormone secreted by adipocytes, which binds to the leptin
receptor and increases partitioning of fatty acids towards
oxidation instead of triacylglycerol formation [7]. In mice
and rats, leptin deficiency causes hyperphagia and obesity
[8]. Moreover, the lack of leptin action causes increased in-
sulin secretion, which is hypothesized to cause insulin re-
sistance in rodents and humans [9]. Insulin resistance
syndrome is hypothesized to cause NAFLD and augment
progression to NASH [10].
T2DM and hepatic steatosis are modeled by a variety
of diet and genetically modified rodent models. Db/db
mice (BKS.Cg-m +/+ Leprdb/J) mice possess a spontan-
eous diabetes (Db) mutation in the leptin receptor. Db/
db mice are insulin resistant, hyperinsulinemic, hypergly-
cemic, glucose intolerant, and possess abnormal islet cell
* Correspondence: aslitt@uri.edu
1Department of Biomedical and Pharmaceutical Sciences, University of Rhode
Island, Kingston, RI 02881, USA
Full list of author information is available at the end of the article
© 2012 More et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
More et al. Comparative Hepatology 2012, 11:1
http://www.comparative-hepatology.com/content/11/1/1
morphology [11-13]. They become hyperinsulinemic
from 10–14 days after birth; and exhibit significant
weight gain with abnormally high triglycerides and low-
and very low-density lipoproteins at 3 to 4 weeks of age.
Hyperglycemia appears after 4–6 weeks of age.
Other mouse models of obesity, diabetes, and NAFLD
exhibit altered transporter expression in liver and kidney
[14]. Transporters are membrane proteins, which facili-
tate chemical transport into and out of cells [15]. Or-
ganic anion transporting polypeptides, organic anion
transporters and organic cation transporters are often re-
ferred to as “uptake transporters”. They are predomin-
antly localized to the basolateral membrane and extract
chemicals from blood into hepatocytes (as reviewed by
[15,16], but it should be noted that Oatps are localized
to the luminal membrane in kidney [17]. Transporters
that are members of the ATP-binding cassette (Abc)
superfamily facilitate efflux of chemicals out of cells; and
include Multidrug resistance proteins (Abcbs), Multidrug
resistance-associated proteins (Abcc), Bile salt-export
pump (Abcb11), and Breast cancer resistance protein
(Abcg2). In liver, Abcc2, Abcg2 and Abcbs are localized
to the canalicular membrane and facilitate biliary excre-
tion of chemicals. Abcc1, 3–6 are localized sinusoidally
and/or basolaterally, and efflux chemicals from hepato-
cytes into blood. In kidney, organic anion and cation
transporters contribute to renal clearance, along with or-
ganic anion transporting polypeptides and Abcc trans-
porters for determining the urinary excretion of many
endogenous chemicals and xenobiotics.
There is evidence in rodents and humans that obesity,
NAFLD, and NASH may increase susceptibility to drug-
induced liver disease (DILI) [18] and exhibit altered ex-
cretion of acetaminophen [19]. Early studies demon-
strated that obese overfed rats, which display NAFLD,
were more sensitive to acetaminophen (APAP)-induced
liver toxicity [18]. Other studies have demonstrated that
obese rats exhibited increased furosemide-induced renal
and hepatic toxicity [20], as well as gentamicin-induced
nephrotoxicity [21]. More recently, studies documented
higher serum and urinary levels of APAP glucuronide
(APAP-G) in children with NAFLD, as compared to con-
trols, after a single dose of APAP [22].
Because obese and diabetic people comprise a significant
portion of the population within the United States, there is
a growing need to better predict drug clearance, DILI, ad-
verse drug effects, and drug efficacy in this population. As
transporters comprise a significant mechanism by which
multiple drugs undergo hepatic and renal clearance, it is
imperative to determine whether diabetes affects trans-
porter expression. The purpose of this study was to com-
pare drug transporter expression levels in normal and
diabetic mice and illustrate that the disposition of a proto-
typical Abcc substrate is altered. The study herein thor-
oughly characterizes drug transporter expression in the
db/db model, which can provide guidance for disposition/
toxicology studies in diabetics. In the present study, trans-
porter mRNA and protein expression was markedly chan-
ged in db/db mice, which exhibit a severe diabetes
phenotype and NAFLD. Moreover increased excretion of
APAP metabolites into urine was observed in db/db mice.
Results
Tissue and body weights, blood glucose levels, and liver
histopathologic evaluation in C57BKS and db/db mice
Table 1 illustrates the body weights, liver and kidney
weights and blood glucose levels of C57BKS and db/db
mice at 9 weeks of age. Body weights for db/db mice were
1.7 and 2.1 times higher than C57BKS males and females,
respectively. Db/db male and female mice had liver weights
that were 1.8 and 2.1 times greater than those of C57BKS
mice, respectively. At nine weeks of age, blood glucose
levels in db/db mice were elevated about 3-fold.
Histopathological analysis showed mild to moderate
steatosis in male and female db/db mice (Additional file 1:
Figure S1). Both male and female db/db mice exhibited
centrilobular and midzonal hepatocyte microvesicular
vacuolation. Livers of C57BKS mice appeared normal
without vacuolations.
Db/db mice exhibit altered uptake transporter mRNA and
protein expression in liver
Solute carrier proteins are predominantly localized to the
basolateral membrane of hepatocytes and transport chemi-
cals into the hepatocytes and are generally referred to as
uptake transporters. Slco1a1 expression was higher in male
Table 1 Body, liver and kidney weight and blood glucose levels for db/db and C57BKS control micea
Strain Gender Liver Weight (g) Kidney weight (g) Average body weight (g) Liver/Body weight Mean blood glucose levels(mg/dL)
C57BKS Female 0.89 ± 0.03 0.25 ± 0.00 17.75 ± 0.23 0.050 ± 0.001 156 ± 3
Male 1.00 ± 0.02 0.31 ± 0.02 21.89 ± 0.35 0.046 ± 0.001 158 ± 9
Db/db Female 1.88 ± 0.08* 0.28 ± 0.01 37.71 ± 0.60* 0.050 ± 0.001 442 ± 48*
Male 1.87 ± 0.06* 0.33 ± 0.01 38.67 ± 0.44* 0.048 ± 0.001 455 ± 33*
aLivers, kidneys, and blood were collected from C57BKS and db/db mice at 9 weeks of age. (*) indicates values significantly different from control (p≤ 0.05). All
weights expressed in grams ± SEM. Asterisk (*) represents statistically significant difference of parameters between C57BKS and db/db mice (p≤0.05).
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C57BKS mice than in female C57BKS mice (Figure 1A),
which is consistent with C57Bl/6 mice [23]. Slco1a1
mRNA expression was markedly downregulated in livers
of male and female db/db mice. Slc10a1 (Ntcp) mRNA ex-
pression was increased in db/db females as compared to
C57BKS females.
Figure 1B illustrates the relative protein expression of
Slco1a1 and 1b2 in crude membrane fractions isolated
from livers of C57BKS and db/db mice. Figure 1C shows
the quantification of western blots in Figure 1B. Slco1a1
protein levels were markedly downregulated in livers of
db/db mice. Slco1b2 protein expression in liver was also
markedly downregulated by about 50% in db/db males
and females as compared to C57BKS mice.
Db/db mice exhibit altered efflux transporter mRNA and
protein expression in liver
Multidrug resistance-associated proteins are efflux trans-
porters that facilitate efflux of chemicals out of hepatocytes
into bile or blood. Figure 2 illustrates mRNA and protein
expression of Abc transporters localized to the canalicular
membrane in livers of db/db and C57BKS mice. Abcg2
mRNA expression was higher in C57BKS males than
C57BKS females. Abcc2 mRNA levels in livers of db/db
males and females were 2 and 1.5 fold higher than
C57BKS males, respectively. Abcc2 protein expression was
also upregulated in db/db males as compared to C57BKS
mice. Abcg2 mRNA and protein expression also increased
with the diabetes phenotype, wherein mRNA expression
doubled in db/db males and females. Correspondingly,
Abcg2 protein levels were increased by 50% and 100% in
livers of db/db male and female mice, respectively. Abcb11
and Abcb1 mRNA expression was decreased in db/db
females as compared to C57BKS females.
Figure 3A illustrates mRNA expression for efflux
transporters localized to the sinusoidal and/or basolateral
membrane. Db/db males have higher expression of
Abcc5 than db/db females. In general, db/db mice dis-
play increased Abcc transporter expression as compared
to C57BKS mice. Db/db male mice expressed Abcc3 and
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Figure 1 Uptake transporters Slco1a1, 1b2 and Slc10a1 expression in livers of C57BKS and db/db mice (n = 8). A) Messenger RNA
expression for Slco1a1, 1b2 and Slc10a1. Total RNA was isolated from livers of adult db/db and C57BKS mice, and mRNA was quantified using the
Branched DNA signal amplification assay. The data is plotted as average Relative Light Unit (RLU) per 10μg total RNA ± SEM. Asterisks (*) represent
a statistically significant expression difference between db/db mice and C57BKS control mice of same gender (p≤0.05). Number signs (#)
represent a significant expression difference between genders, i.e. male and female C57BKS or male and female db/db mice. B) Slco protein
identification and quantification by western blot in crude membrane fractions from livers of C57BKS and db/db mice. Proteins (75 μg/lane) were
separated on 4–20% acrylamide/bis PAGE, transblotted, incubated with primary and secondary antibodies, and visualized by fluorescence. C)
Quantification of western blots by using the Quantity OneW software (Biorad, Hercules, CA). The average band intensity for C57BKS males was set
to 100% and other groups were normalized to that density. Asterisks (*) represent a statistically significant difference between average band
intensity as compared to that of C57BKS males (p≤0.05). Slco1a1 mRNA and protein expression were downregulated in both male and female db/
db mice as compared to controls. Slco1a4 (data not shown) and 1b2 mRNA expression remained unchanged but Slco1b2 protein expression was
downregulated in db/db females. Slc10a1 mRNA expression was upregulated in db/db females as compared to C57BKS females.
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4 mRNA levels in liver that were 2.7 and 2.4 fold higher,
respectively, than C57BKS males. Db/db female mice
expressed Abcc3 and 4 mRNA almost 1.8 fold more than
C57BKS females. Abcc5 mRNA expression in liver was
unchanged in females, but was increased 1.3-fold in
livers of db/db males. Abcc6 mRNA expression was un-
altered in livers of db/db females, but was 2.1 fold higher
in db/db males than that in C57BKS males.
Figures 3B and C illustrate Abcc protein expression in
crude membrane fractions isolated from livers of male
and female db/db and C57BKS mice. Abcc1, 2, 4 protein
expression in liver did not differ between males and
females. Abcc6 protein expression in liver was higher in
females than males. Abcc1 protein expression was sig-
nificantly upregulated by 5- and 2.6-fold in male and fe-
male db/db mice, respectively. Liver Abcc3 and 4 protein
expression was 3–4 fold higher in db/db mice compared
to C57BKS mice. Increased sinusoidal/basolateral Abcc3
staining was also observed in livers of male db/db mice
(Figure 4). The staining observed was consistent with
that previously reported [24]. Db/db females also
expressed increased Abcc6 protein levels in liver did not
differ between db/db and C57BKS mice.
Db/db mice exhibit altered transporter mRNA and protein
expression in kidney
Slco1a1, 1a6, Slc22a1, Slc22a2, Slc22a6, Slc22a7, Abcc1-4,
Abcb1, Abcg2 mRNA expression was quantified in kid-
neys of db/db and C57BKS mice (Figures 5 and 6). Basal
expression of Slco1a1 mRNA in males was more than
females, in both phenotypes. Also, Slc22a2 and 22a6
mRNA was expressed more in C57BKS males than
C57BKS females. Slco1a1 mRNA expression was signifi-
cantly lower in kidneys of db/db than that expressed in
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Figure 2 Canalicular efflux expression in liver of db/db and C57BKS mice. A) Messenger RNA expression for Abcc2, Abcg2, Abcb11 and
Abcb1. Total RNA was isolated from liver, and mRNA was quantified using branched DNA signal amplification assay. The data plotted as average
Relative Light Unit (RLU) per 10 μg total RNA ± SEM. Asterisks (*) represent a statistically significant expression difference between C57BKS and
db/db mice of same gender (p≤0.05). Number signs (#) represent a statistically significant expression gender difference between male and female
db/db mice, or male and female C57BKS mice. B) Abcc2 and Abcg2 protein identification and quantification by western blot in crude membrane
fractions from livers of C57BKS and db/db mice. Proteins (75μg/lane) were separated on 4–20% acrylamide/PAGE, transblotted, incubated with
primary and secondary antibodies, and visualized by fluorescence. C) Quantification of western blots by using the Quantity OneW software (Biorad,
Hercules, CA). The average band intensity for C57BKS males was considered 100% and other groups were compared with that density. Asterisks (*)
represent a statistically significant difference between average band intensity as compared to that of C57BKS males (p≤0.05). Abcc2 mRNA
expression increased in both male and female db/db mice, whereas protein expression increased in db/db males as compared to respective
controls. In db/db females, both mRNA and protein expression of Abcg2 was upregulated, and in db/db males, Abcg2 mRNA was not significantly
upregulated but the protein was significantly up. Abcb11 and Abcb1 mRNA expression was down in db/db females as compared to C57BKS females.
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C57BKS mice, with expression approaching undetectable
levels. Slco1a1 protein expression was also decreased in
db/db females as compared to C57BKS females. In female
db/db mice, Slco1a6 mRNA expression was decreased to
only about 40% of that detected in kidneys of C57BKS
females. Slc22a7 expression was markedly lower in kidneys
of male and female db/db mice as compared to C57BKS
controls. Slc22a6 mRNA expression was unchanged in
kidneys of db/db females, but in db/db males was signifi-
cantly reduced to about one third of that expressed in
kidneys of male C57BKS mice. Slc22a2 mRNA expression
was decreased to about 25% of controls in kidneys of
male db/db mice, but was similarly expressed in kidneys
of db/db and C57BKS females. Slc22a1 mRNA expression
in kidneys was similar between genotypes.
Among efflux transporters, expression of Abccs was
altered in kidneys of db/db mice. Db/db females exhib-
ited marked down regulation of Abcc3 mRNA in kidney
compared to C57BKS female mice. Basal Abcc3 mRNA
expression was markedly higher in female kidneys as
compared to male kidneys, which is consistent with
other published studies [14]. Abcc4 mRNA expression
was unchanged in db/db females, but was significantly
increased, by almost 3-fold in kidneys of db/db male
mice, as compared to that detected in male C57BKS
mice. Also, basal expression of Abcc4 mRNA as well as
Figure 3 Multidrug resistance-associated protein Abcc1, 3–6 expression in livers of C57BKS and db/db mice. A) Messenger RNA
expression for Abcc1, 3, 4, 5 and 6. Total RNA was isolated from livers of adult db/db and C57BKS mice, and mRNA was quantified using branched
DNA signal amplification assay. The data plotted as average Relative Light Unit (RLU) per 10 μg total RNA ± SEM. Asterisks (*) represent a
statistically significant difference of expression between C57BKS and db/db mice of same gender (p≤0.05). Number sign (#) represents statistically
significant expression difference between male and female db/db mice and male and female C57BKS mice. B) Abcc1, 3, 4, and 6 identification
and quantification by western blot in crude membrane fractions from livers of C57BKS and db/db mice. Proteins (75 μg/lane) were separated on
4–20% acrylamide/bis PAGE, transblotted, incubated with primary and secondary antibodies and visualized by fluorescence. C) Quantification of
western blots by using the Quantity OneW software (Biorad, Hercules, CA). The average band intensity for C57BKS males was considered 100% and
other groups were compared with that density. Asterisks (*) represent a statistically significant difference between average band intensity as
compared to that of C57BKS males (p≤0.05). Abcc1 mRNA was unchanged but protein expression was upregulated in both male and female db/
db mice. Abcc3 and 4 mRNA as well as protein expression was upregulated in both male and female db/db mice. Abcc5 and 6 mRNA expression
was upregulated in db/db males, but remained unchanged in females.
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protein in female kidney was almost 3-fold higher than
that expressed male kidney. Abcc2 mRNA expression in
kidney did not differ between db/db and C57BKS mice
for either gender (data not shown).
Db/db mice exhibit altered nuclear receptor and receptor
target gene expression
The relative expression of the transcription factor, nuclear
factor E2 related factor 2 (Nrf2), as well as nuclear hor-
mone receptors peroxisome proliferator activated receptor
alpha (Ppar-α), constitutive androstane receptor (Car), far-
nesoid-X-receptor (Fxr) and pregnane-X-receptor (Pxr)
mRNA expression was quantified in livers of db/db mice
(Figure 7). In both male and female db/db mice, Nrf2
mRNA expression was significantly increased compared to
C57BKS controls. Glutamate cysteine ligase (Gclc), a Nrf2
target gene, was correspondingly increased in livers of db/
db mice. Ppar-α, and its target gene Cyp4a14 mRNA ex-
pression were also higher in male and female db/db mice
as compared to C57BKS mice. Similarly, Car and Cyp2b10
expression also increased in male db/db mice as compared
to C57BKS. Female db/db mice also displayed increased
Cyp2b10, however, Car was unchanged. Pxr mRNA
expression was not altered, however, its target Cyp3a11
expression was increased in db/db males. Similarly, Fxr
mRNA did not increase significantly, however, one of its
target genes, small heterodimer partner (Shp) was
increased in db/db females compared to C57BKS females.
Db/db mice exhibit increased urine APAP and APAP
metabolites levels, and enhanced expression of UDP
glucuronosyl transferase (Ugt) 1a6 and sulfotransferase
(Sult) 1a1
Prior work in male rats demonstrated that APAP-G is a
substrate for mouse and rat Abcc3 [25], and induction of
Abcc3 expression in liver is associated with increased vec-
torial excretion of APAP-G [26,27]. Additionally, in mice,
Abcc3 and 4 contribute to the basolateral excretion of
APAP-sulfate (APAP-S) [25]. Because of Abcc3 and 4 trans-
porters expression was significantly elevated in livers of db/
db mice, and Abcc4 expression was significantly elevated in
kidney, an additional study aimed to explore whether
APAP-G and –S excretion into urine was increased. There-
fore, a low, non-toxic APAP dose (100 mg/kg, po) was
administered to male C57BKS and db/db mice, and of the
total amount of urine APAP-G and APAP-S was quantified
elaMSKB75CelameFSKB75C
elaMbd/bDelameFbd/bD
10 µ 01m µm
10 µm 10 µm
Figure 4 Immunohistochemical staining of liver sections for Abcc3 detection. Frozen livers were cut to 5 μm cryosections and fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS). Sections were blocked in goat serum followed by incubation with anti-Abcc3. Sections
were washed with PBS and incubated with goat anti-rat IgG conjugated to Alexfluor 488 (green staining) and rhodamine-conjugated phalloidin
(red). Sections were then rinsed with PBS/T, PBS, and water, air dried, and then mounted with Prolong Gold containing DAPI (blue staining). All
images are displayed as 200X magnification. It was observed that green staining displaying Abcc3 expression was higher in db/db male and
female mice as compared to controls.
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24 hours after administration (Figure 8A). Urine flow rates
were average 1 mL/24 hr for C57BKS and 2.7 mL/24 hr for
db/db male mice. Taking differences in body weight into
account, urine APAP-G and APAP-S amounts in urine
were twice as high as that in urines from C57BKS mice.
Thus, cumulative excretion of APAP conjugation metabo-
lites was higher in db/db mice. As Ugt1a6 and Sult1a1 are
primary conjugation enzymes for APAP-G and APAP-S
production [28,29], their mRNA expression was evaluated
(Figure 8B). Ugt1a6 and Sult1a1 mRNA expression was
increased in male db/db mice as compared to C57BKS
mice, which corresponded with increased APAP-G and
APAP-S levels in urine.
Discussion
The current study demonstrates that db/db mice, which
are a widely used rodent model of diabetes with exces-
sive weight gain and NAFLD, display profound alteration
of transporter expression in both liver and kidney at the
level of mRNA and protein expression. These observa-
tions are in agreement with [14] and [30]. Increased
urine APAP-G and –S levels were also observed, which
consistent with enhanced APAP-G disposition observed
in other rodent steatosis models [19]. Slco1a1 expression
was markedly downregulated in livers and kidneys of db/
db mice. As Slco1a1 mediates transport of wide variety
of anionic, cationic, zwitterionic, as well as, neutral che-
micals [31], a significant decrease in Slco1a1 expression
in liver and kidney could cause marked changes in
pharmacokinetics and toxicity in the db/db mouse
model. Along with Slco1a1, Slco1b2 protein expression
was significantly decreased in livers of db/db female
mice. In mice, Slco1a1, transports similar substrates as
SLCO1A2, 1B1 and 1B3 in humans [32]. As Ppar-α has a
central role in the down regulation of Slco1a1 in mouse
liver [33,34], and is upregulated in db/db liver, according
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Figure 5 Uptake transporter Slco1a1, 1b2, 1a6, Slc22a6, Slc22a7, Slc22a1 and Slc22a2 expression in kidneys of C57BKS and db/db
mice. A) Messenger RNA expression of uptake transporters in kidneys of C57BKS and db/dB mice. Total RNA was isolated from kidneys of these
mice, and mRNA was quantified by the branched DNA signal amplification assay. The data is plotted as average RLU per 10 μg total RNA ± SEM.
B) Protein expression of Slco1a1 and 1b2 in crude membrane fractions from kidneys of C57BKS and db/db mice (n = 2). Proteins (75 μg/lane) were
separated on 4–20% acrylamide/bis PAGE, transblotted, incubated with primary and secondary antibodies and visualized by fluorescence. C)
Quantification of western blots by using the Quantity OneW software (Biorad, Hercules, CA). The average band intensity for C57BKS males was
considered 100% and other groups were compared with that density. Asterisks (*) represent a statistically significant expression difference
between db/db mice and C57BKS control mice of the same gender (p≤0.05). Number signs (#) represent a statistically significant expression
difference between male and female db/db mice or male and female C57BKS mice (p≤0.05). Slc22a7 mRNA expression was downregulated in db/
db male and female mice. Slco1a1, Slc22a2 and 22a6 mRNA expression was downregulated in db/db males as compared to C57BKS males.
Slco1a1, Slc22a2 and 22a6 mRNA expression was more in C57BKS males as compared to C57BKS females. Slco1a1 and 1b2 protein expressions
were significantly decreased in db/db females as compared to C57BKS females.
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to present study as well as previous findings [35], it is
possible that the observed downregulation is via a Ppar-α
mediated mechanism. Also, as Fxr has been observed to
be decreased in NALFD [36], it is possible Fxr-dependent
mechanisms regulate Slco expression. Fxr regulates
mouse Slco1a1, 1a4 and 1a5 [37]. Pxr also regulates
Slco1a4 expression in mice [38]. Similarly, human
SLCO1B3 and 1A2 is regulated, in part, by FXR [39].
However, db/db mice did not demonstrate any significant
differences in mRNA expression of Fxr and Pxr in liver,
suggesting that in the observed Slco decrease in Db/Db
mice may be due to Ppar-α activation, and not Pxr and
Fxr alterations. These observed changes in Slco expres-
sion in db/db mice could be predicative of SLCO expres-
sion changes in livers of diabetic humans. Further
studies, which reveal nuclear receptor binding to specific
response elements present in Slco promoters, will further
elucidate how these transporters are regulated in leptin/
leptin receptor deficient diabetes models.
The regulation of renal transporter expression in
mouse models of diabetes and obesity remains limited.
Data in this manuscript and Cheng et al. [14] indicate
that a severe diabetes phenotype alters renal transporter
expression. It is intriguing that kidney transporter ex-
pression was substantially altered in this model, but min-
imal changes in renal pathology were observed. In
humans SLC22A6 and SLC22A7 are predominant trans-
porters localized to the basolateral membrane of renal
proximal tubule cells [40]. The SLCs transport certain
antibiotics like benzylpenicillin, antivirals and NSAIDs
Av
er
ag
e 
RL
U/
10
g 
To
ta
l R
N
A 
0 
5000 
10000 
15000 
20000 
Abcc4 
0 
5000 
10000 
15000 
20000 
25000 
Abcc3 
 # 
 # 
   * 
   *    * 
 # 
C57BKS  
Db/db  
A.   B.   C57BKS 
Male 
C57BKS 
Female 
Db/db 
Female 
Db/db 
Male 
0 
200 
400 
600 
800 
Abcc4 Protein 
C.   
Abcc4 
Gapdh 
Pe
rc
en
t e
xp
re
ss
io
n 
0 
1000 
2000 
3000 
4000 
5000 
Abcb1 
   * 
Female Male 
Figure 6 Efflux transporter expression in kidneys of C57BKS and db/db mice. A) Messenger RNA expression of Abcc3, 4 and Abcb1. Total
RNA was isolated from kidneys of adult db/db and C57BKS mice, and mRNA expression was quantified using the branched DNA signal
amplification assay. The data plotted as average RLU per 10 μg total RNA ± SEM. B) Protein expression of Abcc4 from crude membrane fractions
of kidneys of C57BKS and db/db mice (n = 2). Proteins (75 μg/lane) were separated on 4–20% acrylamide/bis PAGE, transblotted, incubated with
primary and secondary antibodies and visualized by fluorescence. C) Quantification of western blot by using the Quantity OneW software (Biorad,
Hercules, CA). The average band intensity for C57BKS males was considered 100% and other groups were compared with that density. Asterisks (*)
represent a statistically significant expression difference between db/db mice and C57BKS mice of the same gender (p≤0.05). Number signs (#)
represent a statistically significant expression difference between male and female db/db mice or male and female C57BKS mice. Abcc3
expression was downregulated in db/db females and upregulated in db/db males as compared to respective controls. Abcc4 mRNA expression
was upregulated in db/db males as compared to C57BKS males. Abcc1, 2, Abcg2 mRNA expression also remained unchanged in kidneys of these
mice (data not shown).
More et al. Comparative Hepatology 2012, 11:1 Page 8 of 14
http://www.comparative-hepatology.com/content/11/1/1
(Non-steroidal anti-inflammatory drugs). Slc22a7 expres-
sion was virtually undetectable in db/db male and female
mice as compared to respective C57BKS controls, indi-
cating the possibility of different renal elimination of
substrates such as antibiotics, antivirals and non-ster-
oidal anti-inflammatory drugs in this model. Slc22a6 and
Slc22a2 expression was also downregulated in db/db
mice, especially males. The mechanism for the observed
Slc downregulation was not determined, however HNF1
has been described to regulate human and mouse
SLC22A7/Slc22a7 and HNF4 has been described to
regulate SLC22A7 in kidney [41,42].
Efflux transporters, in general, were upregulated in
livers of db/db mice. Abcc3 transports mono-ionic bile
acids such as glycocholate and taurocholate [43], as well
as glucuronide or glutathione conjugates of certain drugs
(e.g. APAP-G and morphine-3-glucuronide) [44]. Abcc3
and 4 expressions were significantly upregulated in
db/db mice livers, in both genders. Abcc4 also transports
bile acids, antiviral drugs, and cyclic nucleotides [15], but
also contributes to the basolateral excretion of APAP-S
[45,46]. Reisman et al. demonstrated increased plasma
APAP-G and APAP-S concentrations correspond with
increased Abcc3 and 4 protein expression, respectively
[47]. Additionally, in a rat model of NASH, it was
observed that increased Abcc3 expression enhanced
urinary excretion of APAP-G [19]. Increased expression
of Abcc3 and/or Abcc4 is associated with enhanced ex-
cretion of APAP metabolites [19,48]. In the present
study, db/db mice had higher amounts of APAP-G and
-S metabolites in urine, which was consistent with
increased hepatic Abcc3 expression, and increased hep-
atic and renal Abcc4 expression. The reasons for higher
excretion of APAP-G and APAP should be due to
enhanced production of APAP-G and –S and/or
enhanced basolateral excretion. Db/db mice also display
increase in mRNA expression of the enzymes responsible
for production of major conjugation metabolites like
Ugt1a6 and Sult1a1 compared to C57BKS mice livers
(Figure 8). Therefore, enhanced excretion of glucuronide
and sulfate metabolites was expected. Overall, this data
is consistent with published findings in children with
NAFLD [22]. Increased APAP-G levels were observed in
plasma and urine samples from children presenting with
NAFLD [22]. Abcc1, 2, 4, and Abcg2 mRNA and/or pro-
tein expression was increased in liver, which is consistent
with what was observed in livers of T2DM rats [49].
Abcc1 and Abcg2, along with Abcb1, can transport the
antidiabetic drug rosiglitazone [50]. Severe liver injury
has been reported in a person with T2DM [51] and cho-
lestatic injury has also been observed after rosiglitazone
therapy [52] – both suggesting hepatic clearance is ne-
cessary. Perhaps, differences in expression of these trans-
porters in the diabetic liver could contribute to
decreased hepatic clearance of rosiglitazone. An interest-
ing observation is that rosiglitazone increases the inci-
dence of cardiovascular disease in diabetic patients [53].
As its use is still approved, determining whether diabetes
Av
er
ag
e 
RL
U/
 1
0µ
g 
to
ta
l R
NA
 
 
0 
2000 
4000 
6000 
8000 
Nrf2 
0 
10000 
20000 
30000 
40000 
Gclc 
0 
7000 
14000 
21000 
28000 
35000 
42000 Ppar-  
0 
25000 
50000 
75000 
100000 
125000 
150000 
Cyp4a14 
0 
200 
400 
600 Fxr 
0 
1000 
2000 
3000 
4000 
Shp 
Female  Male  
0 
5000 
10000 
15000 
Car 
0 
200 
400 
600 
Pxr 
0 
10000 
20000 
30000 
40000 
Cyp2b10 
0 
100000 
200000 
300000 
Cyp3a11 
Female  Male  Female  Male  Female  Male  Female  Male  
C57BKS  
Db/db  
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
# 
# 
# 
# # 
# # 
# 
Figure 7 Trascription factor Nrf2, and nuclear receptor Ppar-α, Fxr, Pxr, Car and their target genes mRNA expression in livers of
C57BKS and db/db mice. Messenger RNA expression of Nrf2, Ppar-α, Fxr, Pxr, Car, Gclc, Cyp4a14, Cyp2b10, Cyp3a11 and Shp was quantified.
Total RNA was isolated from livers of adult db/db and C57BKS mice, and mRNA expression was quantified using the branched DNA signal
amplification assay. The data plotted as average RLU per 10 μg total RNA ± SEM. Asterisks (*) represent a statistically significant expression
difference between db/db mice and C57BKS mice of the same gender (p≤0.05). Number signs (#) represent a statistically significant expression
difference between male and female db/db mice or male and female C57BKS mice. Nrf2 and its target gene Gclc display increase in male as
well as female db/db mice, as compared to respective C57BKS controls. Similarly, Ppar-α and Cyp4a14 expression also increased in db/db
mice. Car expression was increased in male db/db mice, and its target gene Cyp2b10 expression was also increased in male as well as female
db/db mice. Fxr expression was unaltered in both male and female db/db mice, however, Shp, a target gene of Fxr, displayed increase in
female db/db mice as compared to C57BKS females. Similarly, Pxr expression wasn’t altered, however, it’s target gene Cyp3a11 expression was
increased in male db/db mice.
More et al. Comparative Hepatology 2012, 11:1 Page 9 of 14
http://www.comparative-hepatology.com/content/11/1/1
could impede rosiglitazone clearance is important for
predicting persons at risk.
The transporters analyzed in this study are known to
be regulated by different mechanisms, involving various
transcription factors such as Ppar-α, Pxr, constitutive
androstane receptor (Car), nuclear factor E2-related fac-
tor 2 (Nrf2), Fxr, and Hepatocyte nuclear factor 1-alpha
(Hnf-1α). Li and Klaassen (2004) showed that HNF1α
levels are critical for constitutive expression of Slco1b2
in mouse liver [54]. Also Slc22a6 and Slc22a7 expression
in mouse kidneys is downregulated by targeted disrup-
tion HNF1α [55]. Significantly reduced expression of
Slco1a1 in liver, along with Slc22a7 in kidney in db/db
mice suggests that HNF1α levels or binding is decreased
in these mice. Similarly, Abcc3 and Abcc4 efflux trans-
porter expression is regulated in part by Nrf2-keap1
pathway in liver [24]. The present study clearly demon-
strates that Abcc2-4 were upregulated in livers of db/db
mice, which suggests activation of the Nrf2 and/or con-
stitutive androstane pathways in these mice. Increased
mRNA expression of Nrf2 and its target gene Gclc indi-
cate that Nrf2-keap1 pathway is likely activated in db/db
mice. The Nrf2-keap1 pathway is activated during peri-
ods of oxidative stress [56]. Also as reviewed by Rolo
and Palmeira, diabetes is typically accompanied by
increased production of free radicals, present findings
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suggests that oxidative stress may be present in diabetic
liver [57]. Together, the data presented argue for add-
itional future studies to better define nuclear receptor
pathways that are upregulated in leptin/leptin receptor
deficient models, which will aid in better understanding
receptor-mediated mechanisms, which could regulate
transporter expression in steatosis and T2DM. As
reviewed by Klaassen and Slitt [38], Car and Pxr are also
known for regulating Abcc2, 3, 5, 6 and Abcc2, 3 re-
spectively. The observed increase in Abcc2, 3, 5, and 6
expression could be attributed to the observed increased
in Car expression and activity, as shown in Figure 7.
Similar to the liver, transporter expression is markedly
altered in kidneys of db/db mice. Maher and colleagues
showed that targeted disruption in Hnf1α significantly
downregulated Slc22a6, 7 and 8 and Slco1a1 mRNA in
mice kidneys [55]. This indicates that db/db mice might
have differential expression or binding of Hnf1α. Also,
these mice have severe hyperglycemia. During normal
course, almost all of the glucose is absorbed from the
nephrons during urine formation. But due to over-
whelming amounts of glucose in glomerular filtrate, kid-
neys are unable to absorb it and thus excrete glucose in
urine. This hyperglycemic urine may cause some altera-
tions in transporter expression in kidneys.
Conclusions
Data illustrated in the present study illustrate a compre-
hensive, panoramic view of how a severe diabetes pheno-
type affects liver and kidney transporter expression in
mice. These changes were associated with altered excre-
tion of the APAP metabolites, APAP-G and –S, which is
consistent with a recent publication in children with
NAFLD [22]. Changes in transporter expression could,
in part, explain why certain drugs have altered ADME in
humans with diabetes. In summary, we demonstrate that
db/db mice, which exhibit a severe diabetes phenotype
display marked alterations in transporter expression in
liver and kidney.
Methods
Animals and husbandry
Seven-week-old C57BKS and db/db (BKS.Cg-m +/+
Leprdb/J, Jax mice stock # 000642) mice (n = 8, for each
strain and gender) were purchased from Jackson Labora-
tories (Bar Harbor, ME). Mice were housed for 2 weeks
under a constant dark/light cycle (12 hr/12 hr) and given
food and water ad libitum. The mice were fed the same
feed (LabDiet 5 K20) as at Jackson laboratories in order
to maintain a consistent food source. During acclima-
tion, body weight and blood glucose levels (Glucose
meter, Bayer Healthcare, Tarrytown, NY) were measured
each week. After 2 weeks of acclimation mice were
anesthetized by isofluorane inhalation – 9 weeks of age
was selected to evaluate expression in db/db mice be-
cause the mice have reached maturity, and exhibit sig-
nificantly elevated blood glucose levels along with
hepatic steatosis, as well as, to compare previous trans-
porter expression observations in ob/ob mice [14]. Blood
was collected and serum was obtained after centrifuga-
tion at 2300xg for 5 minutes at 4°C. Livers and kidneys
were collected, snap frozen in liquid nitrogen, and stored
at −80°C for future analysis. Experiments were approved
by The University of Rhode Island Institutional Animal
Care and Use Committee (IACUC).
RNA extraction
Total RNA from liver and kidney was isolated by phenol-
chloroform extraction using RNA Bee reagent (Tel-Test
Inc, Friendswood, TX) according to the manufacturer’s
protocol. RNA concentration was quantified by absorb-
ance at 260 nm using a spectrophotometer (Nanodrop
ND1000, Thermo Fisher Scientific, Waltham, MA) and the
samples were diluted to 1 μg/μL. Formaldehyde–agarose
gel electrophoresis followed by UV illumination was used
to visualize RNA and confirm integrity.
Oligonucleotide probesets for branched DNA signal
amplification (bDNA) assay
Probe sets for mouse Abcc1-6, Slc22a6, 7, 8, Slco1a1, 1a4,
1b2, 1a6, 2b1, Nrf2, Gclc, Fxr, Shp, Ppar-α, Car, Pxr,
Cyp3a11, Cyp2b10 and Cyp4a14 have been described previ-
ously [23,33,58,59]. Oligonucleotide probesets required for
the assay were graciously donated by Dr. Curtis Klaassen
(University of Kansas Medical Center, Kansas City, KS).
bDNA assay
The Branched DNA assay has been employed in multiple
studies to evaluate relative biotransformation enzyme
and transporter mRNA expression [19,23,33]. All
reagents for analysis including lysis buffer, amplifier/label
probe diluent and substrate solution were supplied in the
QuantiGene 1.0 assay kit (Panomics, Fremont, CA). Oli-
gonucleotides were first dissolved in 10 mM Tris–HCl
(pH 8.0) with 1 mM EDTA and were diluted 1:100 in
lysis buffer before use [60]. On day one, total RNA sam-
ples (10 μg, 1 μg/μL) were added to wells containing 50
μL of capture hybridization buffer and 50 μL of diluted
probe set. The RNA was allowed to hybridize overnight
with probe set at 53°C. On day two, subsequent
hybridization steps were followed as mentioned in man-
ufacturer’s protocol, and fluorescence was measured with
a GloRunnerTM microplate luminometer interfaced with
GloRunner DXL Software (Turner Biosystems, Sunny-
wale, CA). The fluorescence for each well was reported
as relative light units (RLU) per 10 μg of total RNA.
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Preparation of crude membrane preparations from liver
and kidneys
Crude membrane fractions were prepared from livers
and kidney, as this fraction has been previously
described for measurement of transporter expression
[24,61]. Approximately 50 mg of tissue was homoge-
nized in Sucrose-Tris (ST) buffer (250 mM sucrose
10 mM Tris–HCl buffer, pH 7.4) and containing prote-
ase inhibitor cocktail (2 μg/mL, Sigma-Aldrich, Co, St.
Louis, MO). Homogenates were centrifuged at 100,000 g
for 60 min at 4°C. ST buffer (200 μl) was used to re-
suspend the resulting pellet. Protein concentration of
the crude membrane fractions was determined using the
Biorad DC protein assay reagent (Bio-Rad Laboratories,
Hercules, CA).
Western blot analysis of crude membrane fractions
Western blot analysis was used for identification and
quantification of specific transport proteins. Crude mem-
brane fractions (50 μg protein/well) were electrophoret-
ically resolved by SDS-Polyacrylamide gel (4-20%)
electrophoresis. Proteins were transblotted onto polyvi-
nylidene fluoride (PVDF) membrane (Millipore, Bedford,
MA) at 100 V for 45 minutes. The membrane was
blocked overnight at 4°C with 2% non-fat dry milk in
phosphate-buffered saline with 0.05% Tween 20 (PBS/T).
The membrane was then incubated with primary anti-
body in PBS/T for 3 hrs at room temperature. Following
three washes in PBS/T, the membrane was incubated with
species-specific peroxidase-labeled secondary antibody
diluted in PBS/T for 1 hour at room temperature. The
specific information about the source, dilution, type, and
molecular weight of primary and secondary antibodies is
detailed in supplemental information (Additional file 2:
Table S1). After incubation with secondary antibody,
membranes were washed three times in PBS/T, incu-
bated with ECL+ fluorescence Reagent (GE Healthcare,
Buckinghamshire, UK), and developed using autoradiog-
raphy. Protein bands on autoradiographs were quantified
using Quantity OneW software v4.6.3 (Biorad, Hercules,
CA). B-actin or Gapdh were used as loading controls
for western blotting.
Immunohistochemical staining
Abcc3 expression and localization were evaluated because
increased Abcc3 protein expression in liver is associated
with changes in vectorial excretion of acetaminophen-
glucuronide [25]. Frozen tissues were cut into 5 μm sec-
tions on a Vibratome cryostat and were fixed in 4% paraf-
ormaldehyde in phosphate-buffered saline (PBS) for 5
minutes. Sections were washed twice with PBS, for 5 min-
utes at room temperature, and then washed once with PBS
containing 0.2% Triton X-100 (PBS-Triton) for 5 minutes.
Next, sections were incubated with blocking agent (5%
goat serum diluted in PBS-Triton) for 1 hour at room
temperature. Blocking agent was removed and sections
were then incubated with Abcc3 primary antibody (diluted
1:100 in blocking agent) for 2 hours at room temperature.
Sections were washed thrice with PBS-Triton and then
incubated with Alexafluor 488 goat anti-rat IgG antibodies
diluted 1:100 in PBS-Triton and Rhodamine-conjugated
phalloidin (Invitrogen Inc., Carlsbad, CA; diluted 1:200)
for 1 hour at room temperature in dark. After incubation,
sections were washed twice with PBS-Triton, followed by a
wash with PBS, and then double-deionized water. Sections
were allowed to air dry and were mounted with ProlongW
Gold containing DAPI (Invitrogen Inc., Carlsbad, CA).
Acetaminophen (APAP) disposition in C57BKS and db/db
male mice
Ten week old C57BKS and db/db male mice (n = 5) were
obtained from Jackson Laboratories (Bar Harbor, ME).
Only male mice were used for this study, as both genders
exhibited increased liver Abcc3 and 4 expressions, and
APAP disposition studies in rodents are typically per-
formed using males. After two weeks acclimation, mice
were administered APAP (100 mg/kg, po) in 0.9% saline.
Immediately after dosing, mice were housed individually
in metabolic cages equipped with urine collection trays
that kept cool with custom ice packs (Techniplast, USA).
The total urine volume over 24 hrs was measured. To
precipitate proteins in urine, samples (100 μl) were
diluted with 200 μl cold methanol and centrifugated at
4,000 g for 30 min at 4°C. The resulting supernatants
were collected (250 μl) and diluted with 500 μl mobile
phase. After mixed, the samples were centrifuged at
4,000 g for 10 min at 4°C. 100 μl of the supernatant is
used for HPLC analysis. The column used for HPLC
analysis was Eclipse XDB-C18 (4.6 mm x 15 cm,
3.5 μm). The mobile phase A contained 8% methanol
and 1% acetic acid in water, and B contained 50% metha-
nol in water. For first 5 min, mobile phase B was main-
tained at 100% followed by linear gradient of 10 min,
ending in 25% of mobile phase B.
Statistical analysis
Statistically significant differences between groups were
determined by one-way ANOVA followed by a Newman-
Keuls post hoc test. Unless otherwise stated, all data is
presented as mean ± SEM for n= eight mice per group.
For APAP disposition data, t-test was used for statistical
significance. Values with P≤0.05 were considered statisti-
cally significant.
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Additional files
Additional file 1: Figure S1. Title of data: Moderate steatosis db/db
mice. Description of data: Hematoxylin and eosin staining showing mild
to moderate steatosis in female and male db/db mice as compared to
C57BKS mice livers.
Additional file 2: Table S1. Title of data: Primary antibodies for western
blot. Description of data: Type, dilution, molecular weight and sources of
primary antibodies for western blot.
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